American Heart Journal
Volume 151, Issue 6 , Pages 1147-1155 , June 2006

Cardiovascular disease in HIV infection

  • Isabella Sudano, MD

      Affiliations

    • Cardiology, Cardiovascular Center, University Hospital Zürich, Switzerland
    • ,
  • Lukas E. Spieker, MD

      Affiliations

    • Cardiology, Cardiovascular Center, University Hospital Zürich, Switzerland
    • ,
  • Georg Noll, MD

      Affiliations

    • Cardiology, Cardiovascular Center, University Hospital Zürich, Switzerland
    • ,
  • Roberto Corti, MD

      Affiliations

    • Cardiology, Cardiovascular Center, University Hospital Zürich, Switzerland
    • ,
  • Rainer Weber, MD

      Affiliations

    • Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Switzerland
    • ,
  • Thomas F. Lüscher, MD, FESC, FRCP

      Affiliations

    • Cardiology, Cardiovascular Center, University Hospital Zürich, Switzerland
    • Corresponding Author InformationReprint requests: Thomas F. Lüscher, MD, FESC, FRCP, Cardiology Cardiovascular Center, University Hospital, CH-8091 Zürich, Switzerland.

Received 21 July 2004 ,Accepted 30 July 2005.

References 

  1. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165:416–423
  2. Fauci AS. The AIDS epidemic—considerations for the 21st century. N Engl J Med. 1999;341:1046–1050
  3. Joint United Nations Programme on HIV/AIDS (UNAIDS) WHO . AIDS epidemic update: December 2004. Geneva: UNAIDS 2004; 2004;Available at http://www.unaids.org
  4. Peterman TA, Lindsey CA, Selik RM. This place is killing me: a comparison of counties where the incidence rates of AIDS increased the most and the least. J Infect Dis. 2005;191(Suppl 1):S123–S126
  5. Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect. 2000;40:282–284
  6. Moreno R, Villacastin JP, Bueno H, et al. Clinical and echocardiographic findings in HIV patients with pericardial effusion. Cardiology. 1997;88:397–400
  7. Lepori M, Tinguely F, Erard V, et al. Pericardial involvement in an HIV-infected patient. Schweiz Med Wochenschr. 1999;129:736–740
  8. Trautner BW, Darouiche RO. Tuberculous pericarditis: optimal diagnosis and management. Clin Infect Dis. 2001;33:954–961
  9. Hofman P, Drici MD, Gibelin P, et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J. 1993;70:376–381
  10. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur Heart J. 1999;20:447–455
  11. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med. 2002;347:1895–1896
  12. McAllister HA, Hall RJ, Cooley DA. Tumors of the heart and pericardium. Curr Probl Cardiol. 1999;24:57–116
  13. Stotka JL, Good CB, Downer WR, et al. Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest. 1989;95:1359–1361
  14. Kelsey RC, Saker A, Morgan M. Cardiac lymphoma in a patient with AIDS. Ann Intern Med. 1991;115:370–371
  15. Nishikawa Y, Akaishi M, Handa S, et al. A case of malignant lymphoma simulating acute myocardial infarction. Cardiology. 1991;78:357–362
  16. Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003;21:167-84, v-vi.
  17. Pulvirenti JJ, Kerns E, Benson C, et al. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. Clin Infect Dis. 1996;22:40–45
  18. Le Houssine P, Karmochkine M, Ledru F, et al. Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases and review of the literature. Rev Med Interne. 2001;22:1196–1203
  19. Mesa RA, Edell ES, Dunn WF, et al. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc. 1998;73:37–45
  20. Pellicelli AM, Palmieri F, Cicalini S, et al. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci. 2001;946:82–94
  21. Barst RJ, Loyd JE. Genetics and immunogenetic aspects of primary pulmonary hypertension. Chest. 1998;114:231S–236S
  22. Petureau F, Escamilla R, Hermant C, et al. Pulmonary artery hypertension in HIV seropositive drug addicts. Apropos of 10 cases. Rev Mal Respir. 1998;15:97–102
  23. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs. 2001;61:1945–1956
  24. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1846–1850
  25. Speich R, Jenni R, Opravil M, et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly. 2001;131:663–665
  26. Pellicelli AM, Palmieri F, D'Ambrosio C, et al. Role of human immunodeficiency virus in primary pulmonary hypertension—case reports. Angiology. 1998;49:1005–1011
  27. Nair R, Robbs JV, Naidoo NG, et al. Clinical profile of HIV-related aneurysms. Eur J Vasc Endovasc Surg. 2000;20:235–240
  28. Chetty R. Vasculitides associated with HIV infection. J Clin Pathol. 2001;54:275–278
  29. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS. 2003;17(Suppl 1):S70–S76
  30. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710
  31. Monsuez JJ, Gallet B, Escaut L, et al. Clinical outcome after coronary events in patients treated with HIV-protease inhibitors. Eur Heart J. 2000;21:2079–2080
  32. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747–1748
  33. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193
  34. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003
  35. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257–262
  36. Behrens GM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1–infected patients with lipodystrophy. J Clin Invest. 2002;110:1319–1327
  37. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389–397
  38. Chironi G, Escaut L, Gariepy J, et al. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:490–493
  39. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50–55
  40. Carter VM, Hoy JF, Bailey M, et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174–180
  41. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor–associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099
  42. Nicholas PK, Kirksey KM, Corless IB, et al. Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res. 2005;18:55–58
  43. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62
  44. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis. 2004;174:1–10
  45. Ambrose JA, Gould RB, Kurian DC, et al. Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection. Am J Cardiol. 2003;92:301–303
  46. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:313–319
  47. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005;95:586–591
  48. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)–infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627
  49. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:10–14
  50. Hulgan T, Sterling TR, Daugherty J, et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38:277–282
  51. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor–associated hypertriglyceridaemia. AIDS. 2002;16:2195–2200
  52. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811–1822
  53. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046
  54. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207–215
  55. Cofrancesco Jr J, Brown T, Martins CR. Management options for facial lipoatrophy. AIDS Read 2004;14:639-40, 645-50.
  56. Mestres CA, Chuquiure JE, Claramonte X, et al. Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1). Eur J Cardiothorac Surg. 2003;23:1007–1016[discussion 1016]
  57. Chong T, Alejo DE, Greene PS, et al. Cardiac valve replacement in human immunodeficiency virus–infected patients. Ann Thorac Surg. 2003;76:478–480[discussion 480-1]
  58. Halpern SD, Ubel PA, Caplan AL. Solid organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284–287
  59. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1–infected patient with advanced disease. N Engl J Med. 2003;348:2323–2328
  60. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med. 2003;348:2279–2280
  61. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98:3857–3859
  62. Sekigawa I, Koshino K, Hishikawa T, et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J Clin Immunol. 1995;15:312–317
  63. Jain AK, Venkataramanan R, Shapiro R, et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus–positive liver and kidney transplantation patients. Transplant Proc. 2002;34:1540–1541
  64. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433–438

PII: S0002-8703(05)00758-1

doi: 10.1016/j.ahj.2005.07.030

American Heart Journal
Volume 151, Issue 6 , Pages 1147-1155 , June 2006

Article Tools

* Image Usage & Resolution